Vonoprazan

# Vonoprazan ## Overview - **Classification**: Potassium-Competitive Acid Blocker (P-CAB) - **Mechanism**: Reversibly blocks the final step of acid secretion by competing with potassium ions at the H$^+$, K$^+$-ATPase proton pump (acid pump) in gastric parietal cells, leading to rapid and sustained acid suppression. ## Primary Indications 1. **Erosive Esophagitis (EE)**: Healing and maintenance treatment. 2. **H. pylori Eradication**: Combination therapy with antibiotics. 3. **Non-Erosive Reflux Disease (NERD)**: Symptom relief (international studies). ## Adult Dosing ### Standard Dosing **Erosive Esophagitis (Healing)** - **Dose**: **20 mg** - **Frequency**: Once daily (QD) - **Route**: Oral - **Duration**: Up to 8 weeks **Erosive Esophagitis (Maintenance)** - **Dose**: **10 mg** - **Frequency**: Once daily (QD) - **Route**: Oral - **Duration**: Up to 6 months **H. pylori Eradication** - **Dose**: **20 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral - **Duration**: Usually 14 days (with appropriate antibiotics) ### Dose Adjustments - **Renal Impairment**: No dose adjustment needed for mild or moderate impairment (CrCl $\ge$ 30 mL/min). - **Renal Impairment**: Avoid use or use with caution in **severe** impairment (CrCl < 30 mL/min) due to limited data. - **Hepatic Impairment**: No dose adjustment needed for mild impairment (Child-Pugh A). - **Hepatic Impairment**: Use with caution, dose reduction may be necessary in **moderate or severe** impairment (Child-Pugh B or C). - **Elderly Patients**: No specific dose adjustment requirements. ## Pediatric Dosing *Note: Vonoprazan is generally not FDA approved or routinely used in US pediatrics. Dosing below reflects data from developmental programs and international usage where applicable. **Always consult current clinical trial data.** ### Neonates (0-28 days) - **Dose**: Not established. - **Frequency**: Not established. - **Special Notes**: Use in this age group is typically avoided; high risk of adverse effects. ### Infants (1-12 months) - **Dose**: Dosing not standardly defined; clinical trials ongoing. - **Special Notes**: Consideration for use only if benefit outweighs risks. Weight-based dosing is highly variable. ### Children (1-12 years) - **Dose**: Data pending; anticipated starting doses for EE are **5-10 mg** daily. - **Frequency**: Once daily. - **Maximum**: Recommended maximum dose is **10 mg** for healing EE in younger children. ### Adolescents (13-18 years) - **Dose**: Typically treated using **adult dosing** guidelines. - **Maximum**: **20 mg** per day for healing EE. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to vonoprazan or formulation components. - **Absolute**: Co-administration with rilpivirine-containing products (high risk of virologic failure). - **Absolute**: Co-administration with atazanavir or nelfinavir (reduced antiretroviral efficacy). ### Common Adverse Effects - **Very Common (>10%)**: None reported. - **Common (1-10%)**: Diarrhea, abdominal distension, headache, nasopharyngitis. - **Serious but Rare**: *Clostridium difficile* associated diarrhea (CDAD), vitamin B12 deficiency (with long-term use), acute tubulointerstitial nephritis (ATIN). ### Key Drug Interactions - **CYP3A and CYP2B6 Substrates**: Vonoprazan is a strong inhibitor of CYP3A4 and moderate inhibitor of CYP2B6; monitor sensitive substrates (e.g., midazolam, tacrolimus). - **Highly pH-Dependent Drugs**: Vonoprazan significantly increases gastric pH; avoid co-administration of drugs requiring gastric acidity for absorption (e.g., certain antifungals, tyrosine kinase inhibitors, iron salts). - **Clopidogrel**: Unlike some PPIs, vonoprazan does **not** significantly impair clopidogrel metabolism; generally considered a safer option. ## Monitoring & Follow-up - **Before Treatment**: Baseline assessment for *H. pylori* status (if treating for ulcer disease). - **During Treatment**: Symptom relief assessment, monitoring for diarrhea (CDAD risk). - **Clinical Signs**: Watch for signs of B12 deficiency (paresthesia, gait disturbance) with prolonged use (> 1 year). ## Clinical Pearls - 💡 **Tip 1**: Vonoprazan achieves rapid acid suppression and sustained 24-hour pH control, often faster than traditional PPIs. - 💡 **Tip 2**: May be taken **without regard to meals**, increasing patient convenience compared to PPIs. - 💡 **Tip 3**: Counsel patients on the signs of *C. difficile* infection (persistent, watery diarrhea) and to contact provider immediately. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.